ArticleAbdominal radiology (New York)2026
Automatic segmentation-based radiomics and deep learning combined with clinical parameters for precise differentiation of lipid-poor adrenal adenomas and metastases.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status of single port robotic-assisted reconstructive urology: a systematic review, meta-analysis and structured summary of the available literature.Journal of robotic surgery · 2025Pooled it
- AI-enabled precision evaluation of adrenal masses: radiomics, deep learning, and explainable imaging biomarkers.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo explore the application value of a combined model automatic segmentation-based radiomics and deep learning, integrated with clinical parameters, in differentiating adrenal lipid-poor adenomas and metastases.
methodsThis study included totally 535 patients with adrenal tumors. The internal cohort comprised 418 patients, who were randomly divided into a training set (n = 292) and an internal validation set (n = 126) at a 7:3 ratio. A clinical prediction model was developed using multivariate XGBoost algorithm. After automatic segmentation of all images, the volume of interest(VOI) of the lesions was obtained. Radiomic features were extracted from contrast-enhanced abdominal CT images and combined with deep learning signatures. Feature selection and dimensionality reduction were performed using statistical tests, Least Absolute Shrinkage and Selection Operator (LASSO), and Pearson correlation analysis. Traditional radiomics models, a ResNet50 deep-learning model based on convolutional neural networks, and combined prediction models integrating clinical features were constructed. Model performance was evaluated using metrics such as the area under the curve (AUC), sensitivity, and specificity. An external test set of 117 adrenal tumor patients was used to validate the predictive performance of each model. Finally, SHAP plots were applied to enhance model interpretability and quantify the impact of individual features.
resultsThe combined prediction model integrating radiomics, deep-learning features, and clinical parameters outperformed single-feature models, with AUCs of 0.996, 0.939, and 0.852 in the training, internal validation, and external test sets, respectively. This combined model offers superior diagnostic performance and greater clinical benefit.
conclusionThe combined prediction model, which integrates radiomics and deep learning features derived from automatic segmentation with clinical parameters, demonstrates strong predictive value for distinguishing between lipid-poor adrenal adenomas and metastases.
Indexed as
Identifiers
41417084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.